Literature DB >> 19048399

Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer.

Mustafa Akkiprik1, Ozgur Sonmez, Bahadir M Gulluoglu, Hale B Caglar, Handan Kaya, Pakize Demirkalem, Ufuk Abacioglu, Meric Sengoz, Aydin Sav, Ayse Ozer.   

Abstract

p53 polymorphic variants play an important role in the determination of tumor phenotype and characteristics in breast cancer. In this study, we examined three common polymorphisms in p53 gene and their haplotype combinations to assess their potential association with inherited predisposition to breast cancer development, in relations with the protein over-expression and patients' demographic data. A total of 99 patients with breast cancer and 107 age-matched healthy controls were included in the study. Genotypes were determined using PCR-RFLP and DNA sequencing techniques. Evaluation of p53 protein over-expression was also examined by immunohistochemistry. Among three polymorphisms, increased codon 72 Pro allele frequency (p = 0.0067) and the presence of Pro allele were found to be significantly associated with breast cancer (p = 0.013). A significant risk was also found in subjects with combinations of specific haplotypes and genotypes. Most of breast cancer women especially younger than 50 years carry at least one p53 polymorphism (p = 0.001). There was no any association between these three p53 polymorphisms and the protein over-expression, separately or in interaction, with breast cancer. In conclusion, presence of proline allele at codon 72 alone, and its special combinations with other two polymorphisms appear to be a significant risk factor for breast cancer. Determination of well-known p53 polymorphisms might be a good predictor for breast cancer development especially in women younger than 50 years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19048399     DOI: 10.1007/s12253-008-9129-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  36 in total

1.  A rapid procedure for extracting genomic DNA from leukocytes.

Authors:  S W John; G Weitzner; R Rozen; C R Scriver
Journal:  Nucleic Acids Res       Date:  1991-01-25       Impact factor: 16.971

2.  p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients.

Authors:  Pia Wegman; Olle Stal; Marie Stenmark Askmalm; Bo Nordenskjöld; Lars-Erik Rutqvist; Sten Wingren
Journal:  Pharmacogenet Genomics       Date:  2006-05       Impact factor: 2.089

3.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity.

Authors:  Xifeng Wu; Hua Zhao; Christopher I Amos; Sanjay Shete; Nimisha Makan; Waun K Hong; Fred F Kadlubar; Margaret R Spitz
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years.

Authors:  Shan Wang-Gohrke; Heiko Becher; Rolf Kreienberg; Ingo B Runnebaum; Jenny Chang-Claude
Journal:  Pharmacogenetics       Date:  2002-04

7.  Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women.

Authors:  Baharak Khadang; Mohammad Javad Fattahi; Abdolrasol Talei; Alamtaj Samsami Dehaghani; Abbas Ghaderi
Journal:  Cancer Genet Cytogenet       Date:  2007-02

8.  p53 polymorphisms and haplotypes in breast cancer.

Authors:  A Själander; R Birgander; G Hallmans; S Cajander; P Lenner; L Athlin; G Beckman; L Beckman
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

9.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Authors:  Patrick Dumont; J I-Ju Leu; Anthony C Della Pietra; Donna L George; Maureen Murphy
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

10.  p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.

Authors:  Hiroko Yamashita; Tatsuya Toyama; Mariko Nishio; Yoshiaki Ando; Maho Hamaguchi; Zhenhuan Zhang; Shunzo Kobayashi; Yoshitaka Fujii; Hirotaka Iwase
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

View more
  15 in total

1.  Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Authors:  Hongtao Cheng; Biao Ma; Ran Jiang; Wei Wang; Hui Guo; Na Shen; Dapeng Li; Qunzi Zhao; Rui Wang; Pengfei Yi; Yue Zhao; Zeming Liu; Tao Huang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  P53 gene polymorphisms and breast cancer risk in Arab women.

Authors:  Shafika Alawadi; Lina Ghabreau; Mervat Alsaleh; Zainab Abdulaziz; Mohamed Rafeek; Nizar Akil; Moussa Alkhalaf
Journal:  Med Oncol       Date:  2010-05-05       Impact factor: 3.064

3.  Inhibitory Effects of 5-Aza-2'-Deoxycytidine and Trichostatin A in Combination with p53-Expressing Adenovirus on Human Laryngocarcinoma Cells.

Authors:  Ling-Yan Jiang; Meng Lian; Hong Wang; Ju-Gao Fang; Qi Wang
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

4.  Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer.

Authors:  Silvia Rybárová; Janka Vecanová; Ingrid Hodorová; Jozef Mihalik; Martina Čižmáriková; Ján Mojžiš; Peter Solár; Marián Benický; Marian Adamkov; Ladislav Mirossay
Journal:  Med Sci Monit       Date:  2011-12

5.  Intron 3 sixteen base pairs duplication polymorphism of p53 contributes to breast cancer susceptibility: evidence from meta-analysis.

Authors:  Dongmei Wu; Zhizhong Zhang; Haiyan Chu; Ming Xu; Yao Xue; Haixia Zhu; Zhengdong Zhang
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

6.  Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis.

Authors:  Meire Luzia Gonçalves; Sarah Moreira Borja; Jacqueline Andréia Bernardes Leão Cordeiro; Vera Aparecida Saddi; Flávio Monteiro Ayres; Cesar Augusto Sam Tiago Vilanova-Costa; Antonio Márcio Teodoro Cordeiro Silva
Journal:  Springerplus       Date:  2014-12-17

7.  Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression.

Authors:  Liang Li; Ying Xu; Binquan Wang
Journal:  Oncol Lett       Date:  2014-12-29       Impact factor: 2.967

8.  Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population.

Authors:  Chaymaa Marouf; Amal Tazzite; Brehima Diakité; Hassan Jouhadi; Abdellatif Benider; Sellama Nadifi
Journal:  Tumour Biol       Date:  2014-09-09

9.  p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.

Authors:  Jing Hou; Yuan Jiang; Wenru Tang; Shuting Jia
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

10.  Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls.

Authors:  Wenlei Zhuo; Yunsong Zhang; Zhaolan Xiang; Lei Cai; Zhengtang Chen
Journal:  J Exp Clin Cancer Res       Date:  2009-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.